Evidence map›Paper›PMID 27667309›Full record

ReviewThe British journal of dermatology2016

Translating translation into patient benefit for atopic eczema.

N J Reynolds, A Sinha, M S Elias, S J Meggitt

Open access · hybridAbstract readReview
In one paragraph

Review in The British journal of dermatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

N J ReynoldsInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4HH, U.K. nick.reynolds@ncl.ac.uk.
A SinhaInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4HH, U.K.
M S EliasInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4HH, U.K.
S J MeggittInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4HH, U.K.
Newcastle University · GBRoyal Victoria Infirmary · GB

Funding

Wellcome Trust 061178
6 · The paper itself

Abstract

This review considers, in the context of British Skin Foundation (BSF)-funded translational research into atopic eczema conducted in Newcastle, the complex interactions between clinical and non-clinical scientists in both academia and industry and how this may have impacted on clinical care. However, research in individual centres does not occur in isolation and clinically relevant outcomes from collaborative research are increasingly supported through regional and national networks. This is illustrated by our trial of azathioprine in adults with atopic eczema conducted across centres in the North East of England that employed pharmacogenetic dosimetry. Correspondingly the formation of a UK Translational Network for Translational Research in Dermatology (UK TREND) has facilitated the development of a UK-wide network to support atopic eczema projects based on an e-Delphi prioritisation exercise.

Identifiers

PMID27667309
PMCPMC5244670
OpenAlexW2526080009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.